PLRX

Pliant Therapeutics Inc

PLRX, USA

Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company's lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325, a phase 1-ready program for treatment of the muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

https://pliantrx.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
PLRX
stock
PLRX

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Average Rating of "Reduce" by Brokerages MarketBeat

Read more →
PLRX
stock
PLRX

Pliant Therapeutics Announces Departure of Chief Medical Officer TipRanks

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

HOLD

Target Price:

$3.25

Analyst Picks

Strong Buy

1

Buy

1

Hold

11

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.38

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-13.13 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-9.51 %

Low 2%

High 10%

Debt to Equity

-

Very High

0.38

Low 1

High 0.3

Investors

* Institutions hold a combined 76.56% of the total shares of Pliant Therapeutics Inc

1.

TANG CAPITAL MANAGEMENT LLC

(9.7739%)

since

2025/06/30

2.

Deep Track Capital, LP

(6.4309%)

since

2025/06/30

3.

Morgan Stanley - Brokerage Accounts

(6.1146%)

since

2025/06/30

4.

Vanguard Group Inc

(4.8908%)

since

2025/06/30

5.

Blue Owl Capital Holdings LP

(4.8368%)

since

2025/06/30

6.

UBS Group AG

(4.3112%)

since

2025/06/30

7.

Citadel Advisors Llc

(3.8377%)

since

2025/06/30

8.

Woodline Partners LP

(3.8257%)

since

2025/06/30

9.

Madison Avenue Partners, LP

(3.6326%)

since

2025/06/30

10.

TRV GP IV, LLC

(3.4744%)

since

2025/06/30

11.

BlackRock Inc

(3.4706%)

since

2025/06/30

12.

JPMorgan Chase & Co

(3.1902%)

since

2025/06/30

13.

Vanguard Total Stock Mkt Idx Inv

(2.854%)

since

2025/07/31

14.

Redmile Group, LLC

(2.6594%)

since

2025/06/30

15.

Peapod Lane Capital LLC

(1.4559%)

since

2025/06/30

16.

Millennium Management LLC

(1.3854%)

since

2025/06/30

17.

Great Point Partners LLC

(1.3846%)

since

2025/06/30

18.

Prosight Management, LP

(1.3641%)

since

2025/06/30

19.

Monaco Asset Management

(1.1442%)

since

2025/06/30

20.

Goldman Sachs Group Inc

(0.972%)

since

2025/06/30

21.

Geode Capital Management, LLC

(0.949%)

since

2025/06/30

22.

Vanguard Institutional Extnd Mkt Idx Tr

(0.9127%)

since

2025/07/31

23.

iShares Biotechnology ETF

(0.5223%)

since

2025/08/31

24.

Fidelity Extended Market Index

(0.4718%)

since

2025/07/31

25.

Schwab US Small-Cap ETF™

(0.4093%)

since

2025/08/30

26.

Vanguard US Value Factor ETF

(0.3225%)

since

2025/06/30

27.

BLK CDN MSCI USA Sm Cp Ext ESG Fcs Idx A

(0.2227%)

since

2025/03/31

28.

iShares Micro-Cap ETF

(0.2106%)

since

2025/08/31

29.

Vanguard Health Care ETF

(0.1864%)

since

2025/07/31

30.

Extended Equity Market Fund K

(0.169%)

since

2025/06/30

31.

Fidelity Total Market Index

(0.1556%)

since

2025/07/31

32.

Bridgeway Ultra-Small Company Market

(0.1341%)

since

2025/06/30

33.

AST T. Rowe Price Asset Allocation

(0.1284%)

since

2024/11/30

34.

Fidelity Series Total Market Index

(0.125%)

since

2025/07/31

35.

Invesco RAFI US 1500 Small-Mid ETF

(0.1132%)

since

2025/08/29

36.

NT Ext Equity Mkt Idx Fd - NL

(0.1096%)

since

2025/06/30

37.

Spartan Extended Market Index Pool F

(0.1074%)

since

2025/07/31

38.

NT Col R2000 Val Idx Fd -DC -L -TierFour

(0.1041%)

since

2025/03/31

39.

Northern Trust Extended Eq Market Idx

(0.099%)

since

2025/06/30

40.

NT Ext Equity Mkt Idx Fd - L

(0.099%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.4166

Latest Release

Date

2025-09-30

EPS Actual

-0.43

EPS Estimate

-0.56

EPS Difference

0.13

Surprise Percent

23.2143%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(6.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2)
Net Net
Possible Net-Net(5.5)
Quality
Low Quality Business(2.5)
Value
Fair Value(5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.